129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

Launched by BASTIAAN DRIEHUYS · Oct 23, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new type of imaging called 129Xe MRI to help diagnose and monitor a serious condition known as Pulmonary Arterial Hypertension (PAH). PAH is a condition that affects the blood vessels in the lungs, making it hard for blood to flow and leading to various health issues. The goal of the study is to see if 129Xe MRI can help doctors understand different forms of PAH and track how well patients respond to treatments over time. Researchers will also use other tests, like blood tests and walking tests, to gather more information about the patients' health.

To participate in this trial, individuals need to be between 18 and 75 years old and have a specific type of PAH, either Idiopathic PAH (with no known cause) or PAH associated with connective tissue diseases. Participants should have certain measurements related to their heart and lung function, which will help ensure they are a good fit for the study. If someone decides to join, they can expect to undergo the 129Xe MRI scan along with other assessments, contributing to important research that could improve understanding and treatment of PAH.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Arm 1 -IPAH
• • Age: 18-75 years
• • WHO functional class 2 or 3
• • Mean pulmonary artery pressures \> 20 mmHg
• • Pulmonary capillary wedge pressure ≤15 mmHg
• • Pulmonary vascular resistance \> 2 Wood Units (WU)
• • No other cause identified for PAH
• • Arm 2 -PAH-CTD
• • Age: 18-75 years
• • WHO functional class (FC) 2 or 3
• • Mean pulmonary artery pressures \> 20 mmHg
• • Pulmonary capillary wedge pressure ≤15 mmHg
• • Pulmonary vascular resistance \> 2 WU
• • Diagnosis of connective tissue disease
• Exclusion Criteria:
• • PH other than Idiopathic PAH or PAH associated with CTD; any conditions that prevent the performance of 129Xe MRI scans will be excluded from the study.